Clinical Research
CCRM Nordic
CCRM Nordic is a Non for profit company located in Gothenburg. CCRM Nordics core mission is to support the production of ATMP products from early stage to clinical trials, in order to get more products to patients. They also offer CMC support, analytic services, business strategy in the form of market and IP services, company creation and financing, and can support in grants application processes.
Lars Karlsson
Research focuses on the development and clinical translation of CAR T-cell therapies for diffuse midline glioma (DMG/DIPG), an aggressive and currently incurable pediatric brain tumour. The work spans the full translational pipeline, including target antigen validation, CAR T-cell engineering, functional testing in patient-derived tumour models, in vivo evaluation, and preparation for first-in-human clinical studies. Particular emphasis is placed on local delivery of CAR T cells to the central nervous system, tumour microenvironment interactions, and the development of academic ATMP platforms capable of advancing novel cell therapies from preclinical research to clinical implementation.
AstraZeneca
AstraZeneca is global pharma company with strong connection to Sweden through both big research and manufacturing sites. Their development of ATMPs includes CAR-T and TCR-T treatments, as well as drug delivery platforms. Their research as well as product development is spread out globally with over 80 000 employees over the world.
Pia Johansson
Research focuses on health economic evaluation of healthcare interventions, with a particular interest in the unique challenges and opportunities associated with ATMPs. The work examines issues related to value assessment, reimbursement, patient access, and the long-term economic impact of advanced therapies, contributing evidence that supports informed decision-making in healthcare systems.
Lars Kölby
Research focuses on 3D bioprinted tissues for reconstructive surgery, with main focus areas being cartilage & adipose tissue. 3D bioprinting is used to create constructs with a defined shape and utilize patient's own tissue & cells as building blocks to create autologous, living tissue constructs. Right now, focus is on strategies for promoting vascularization and tissue survival, with the aim of generating larger tissues to be used for e.g., breast reconstruction after breast cancer. The goal is to generate personalized tissues capable of reducing the need for synthetic implants or improve traditional methods for tissue transplantation.
Kristin Oskarsdotter
Research focuses on 3D bioprinted tissues for reconstructive surgery, with main focus areas being cartilage & adipose tissue. 3D bioprinting is used to create constructs with a defined shape and utilize patient's own tissue & cells as building blocks to create autologous, living tissue constructs. Right now, focus is on strategies for promoting vascularization and tissue survival, with the aim of generating larger tissues to be used for e.g., breast reconstruction after breast cancer. The goal is to generate personalized tissues capable of reducing the need for synthetic implants or improve traditional methods for tissue transplantation.
Karin Säljö
Research focuses on 3D bioprinted tissues for reconstructive surgery, with main focus areas being cartilage & adipose tissue. 3D bioprinting is used to create constructs with a defined shape and utilize patient's own tissue & cells as building blocks to create autologous, living tissue constructs. Right now, focus is on strategies for promoting vascularization and tissue survival, with the aim of generating larger tissues to be used for e.g., breast reconstruction after breast cancer. The goal is to generate personalized tissues capable of reducing the need for synthetic implants or improve traditional methods for tissue transplantation.
Mikael Lisak
Research focuses on hematology and stem-cell transplantation, including complications and outcomes after transplantation. Clinical use of CAR-T-cell therapy and in particular outcomes in patients with aggressive B-cell lymphomas is of high interest.
Kalliopi Sofou
Research focuses on rare neuromuscular and mitochondrial diseases in children, with particular emphasis on clinical research, patient follow-up, and the implementation of advanced therapies in neurological disorders. The work combines clinical expertise, translational research, and international collaboration to improve diagnosis, treatment, and long-term outcomes for patients with inherited neuromuscular diseases, including conditions where emerging gene and cell therapies are becoming available.
Jan Holgersson
Research in transplant immunology supported by extensive clinical and scientific expertise in transplantation, tissue compatibility and mechanisms of graft rejection. Chairman of the Board of VERIGRAFT, providing scientific, clinical and strategic leadership to the development of personalized tissue-engineered ATMPs, including P-TEV, chair of the ATMP Coordination Group at Sahlgrenska Academy, and active in the ATMP Sweden/Cell & Gene Therapy organization.
Cristina Maglio
Research focuses on systemic sclerosis and other rare autoimmune diseases, with the aim of understanding disease mechanisms and identifying new therapeutic opportunities for conditions with major unmet medical needs. The work combines clinical research with translational immunology, biomarker discovery, advanced cell analysis, and computational approaches to characterize patient populations and disease heterogeneity. Through expertise in patient phenotyping, translational studies, and clinical research, this activity contributes to the development and evaluation of emerging ATMP approaches, including cell-based immunotherapies for autoimmune diseases.
CCRM Nordic
CCRM Nordic, based in Gothenburg, Sweden, supports academic, small, and large industrial ATMP developers to translate research and early-stage clinical programs into treatments for patients.